157 related articles for article (PubMed ID: 3472638)
1. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia.
Borsi JD; Moe PJ
Cancer; 1987 Jul; 60(1):5-13. PubMed ID: 3472638
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
[TBL] [Abstract][Full Text] [Related]
3. Comparative study on the pharmacokinetics of 7-hydroxy-methotrexate after administration of methotrexate in the dose range of 0.5-33.6 g/m2 to children with acute lymphoblastic leukemia.
Borsi JD; Sagen E; Romslo I; Moe PJ
Med Pediatr Oncol; 1990; 18(3):217-24. PubMed ID: 2329967
[TBL] [Abstract][Full Text] [Related]
4. Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia.
Evans WE; Stewart CF; Hutson PR; Cairnes DA; Bowman WP; Yee GC; Crom WR
Drug Intell Clin Pharm; 1982 Nov; 16(11):839-42. PubMed ID: 6959800
[TBL] [Abstract][Full Text] [Related]
5. Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children.
Borsi JD; Moe PJ
Cancer; 1987 Dec; 60(12):3020-4. PubMed ID: 3479231
[TBL] [Abstract][Full Text] [Related]
6. [Studies of methotrexate pharmacokinetics in children with neoplasms of the hematopoietic system after administration of different doses of the drug].
Wysocki M; Krzyzanowski M; Ozyński T; Pilecki O; Balcar-Boroń A; Szadujkis-Szadurski L
Acta Haematol Pol; 1992; 23(3):179-83. PubMed ID: 1492542
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma.
Ettinger LJ; Chervinsky DS; Freeman AI; Creaven PJ
Cancer; 1982 Nov; 50(9):1676-82. PubMed ID: 6956429
[TBL] [Abstract][Full Text] [Related]
8. Prognostic importance of systemic clearance of methotrexate in childhood acute lymphoblastic leukemia.
Borsi JD; Revesz T; Schuler D
Cancer Chemother Pharmacol; 1987; 19(3):261-4. PubMed ID: 3472677
[TBL] [Abstract][Full Text] [Related]
9. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and toxicity of frequent intermediate dose methotrexate infusions.
Parker RI; Forman EN; Krumm KF; Abeel MJ; Martin HF
Ther Drug Monit; 1986; 8(4):393-9. PubMed ID: 3469802
[TBL] [Abstract][Full Text] [Related]
11. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia.
Pinkerton CR; Welshman SG; Kelly JG; Shanks RG; Bridges JM
Cancer Chemother Pharmacol; 1982 Dec; 10(1):36-9. PubMed ID: 6961972
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
Kearns CM; Blakley RL; Santana VM; Crom WR
Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
[TBL] [Abstract][Full Text] [Related]
15. 7-Hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia.
Borsi JD; Sagen E; Romslo I; Slørdal L; Moe PJ
Cancer Chemother Pharmacol; 1990; 27(2):164-7. PubMed ID: 2249335
[TBL] [Abstract][Full Text] [Related]
16. Remission induction of meningeal leukemia with high-dose intravenous methotrexate.
Balis FM; Savitch JL; Bleyer WA; Reaman GH; Poplack DG
J Clin Oncol; 1985 Apr; 3(4):485-9. PubMed ID: 3856631
[TBL] [Abstract][Full Text] [Related]
17. High-dose methotrexate in acute lymphocytic leukemia.
Freeman AI; Wang JJ; Sinks LF
Cancer Treat Rep; 1977 Jul; 61(4):727-31. PubMed ID: 267510
[TBL] [Abstract][Full Text] [Related]
18. Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables.
Seidel H; Andersen A; Kvaløy JT; Nygaard R; Moe PJ; Jacobsen G; Lindqvist B; Slørdal L
Leuk Res; 2000 Mar; 24(3):193-9. PubMed ID: 10739001
[TBL] [Abstract][Full Text] [Related]
19. Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance.
Crom WR; Glynn AM; Abromowitch M; Pui CH; Dodge R; Evans WE
Clin Pharmacol Ther; 1986 May; 39(5):592-7. PubMed ID: 3516513
[TBL] [Abstract][Full Text] [Related]
20. Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies.
Thyss A; Milano G; Deville A; Manassero J; Renee N; Schneider M
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):843-7. PubMed ID: 3477462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
